Literature DB >> 22996690

Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets.

Alicia K Olivier1, Yaling Yi, Xingshen Sun, Hongshu Sui, Bo Liang, Shanming Hu, Weiliang Xie, John T Fisher, Nicholas W Keiser, Diana Lei, Weihong Zhou, Ziying Yan, Guiying Li, Turan I A Evans, David K Meyerholz, Kai Wang, Zoe A Stewart, Andrew W Norris, John F Engelhardt.   

Abstract

Diabetes is a common comorbidity in cystic fibrosis (CF) that worsens prognosis. The lack of an animal model for CF-related diabetes (CFRD) has made it difficult to dissect how the onset of pancreatic pathology influences the emergence of CFRD. We evaluated the structure and function of the neonatal CF endocrine pancreas using a new CFTR-knockout ferret model. Although CF kits are born with only mild exocrine pancreas disease, progressive exocrine and endocrine pancreatic loss during the first months of life was associated with pancreatic inflammation, spontaneous hyperglycemia, and glucose intolerance. Interestingly, prior to major exocrine pancreas disease, CF kits demonstrated significant abnormalities in blood glucose and insulin regulation, including diminished first-phase and accentuated peak insulin secretion in response to glucose, elevated peak glucose levels following glucose challenge, and variably elevated insulin and C-peptide levels in the nonfasted state. Although there was no difference in lobular insulin and glucagon expression between genotypes at birth, significant alterations in the frequencies of small and large islets were observed. Newborn cultured CF islets demonstrated dysregulated glucose-dependent insulin secretion in comparison to controls, suggesting intrinsic abnormalities in CF islets. These findings demonstrate that early abnormalities exist in the regulation of insulin secretion by the CF endocrine pancreas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996690      PMCID: PMC3534166          DOI: 10.1172/JCI60610

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

Review 1.  Pathophysiology of the exocrine pancreas in cystic fibrosis.

Authors:  P R Durie; G G Forstner
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

2.  Increased plasma cholecystokinin levels and small gall bladders in adult patients with cystic fibrosis.

Authors:  E H van Haren; W P Hopman; J B Jansen; G Rosenbusch; C B Lamers; C L van Herwaarden
Journal:  Clin Sci (Lond)       Date:  1991-07       Impact factor: 6.124

3.  Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury.

Authors:  Michael S Stalvey; Christian Muller; Desmond A Schatz; Clive H Wasserfall; Martha L Campbell-Thompson; Douglas W Theriaque; Terence R Flotte; Mark A Atkinson
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

4.  Serum cortisol radioimmunoassay values in the normal ferret and response to ACTH stimulation and dexamethasone suppression tests.

Authors:  B A Garibaldi; M E Pecquet Goad; J G Fox; T J Sylvina; R Murray
Journal:  Lab Anim Sci       Date:  1988-08

5.  Spontaneous hypoglycemia in patients with cystic fibrosis.

Authors:  A Battezzati; P M Battezzati; D Costantini; M Seia; L Zazzeron; M C Russo; V Daccò; S Bertoli; A Crosignani; C Colombo
Journal:  Eur J Endocrinol       Date:  2007-03       Impact factor: 6.664

6.  Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance.

Authors:  Roger Gutiérrez-Juárez; Alessandro Pocai; Claudia Mulas; Hiraku Ono; Sanjay Bhanot; Brett P Monia; Luciano Rossetti
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

7.  Insulin sensitivity in cystic fibrosis.

Authors:  A Moran; K L Pyzdrowski; J Weinreb; B B Kahn; S A Smith; K S Adams; E R Seaquist
Journal:  Diabetes       Date:  1994-08       Impact factor: 9.461

8.  Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis.

Authors:  A Austin; S C Kalhan; D Orenstein; P Nixon; S Arslanian
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

9.  Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; J Nerup; C Koch
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

10.  Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study.

Authors:  M Löhr; P Goertchen; H Nizze; N S Gould; V E Gould; M Oberholzer; P U Heitz; G Klöppel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989
View more
  69 in total

Review 1.  CFTR pharmacology.

Authors:  Olga Zegarra-Moran; Luis J V Galietta
Journal:  Cell Mol Life Sci       Date:  2016-10-04       Impact factor: 9.261

2.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

3.  Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets.

Authors:  Xingshen Sun; Alicia K Olivier; Yaling Yi; Christopher E Pope; Hillary S Hayden; Bo Liang; Hongshu Sui; Weihong Zhou; Kyle R Hager; Yulong Zhang; Xiaoming Liu; Ziying Yan; John T Fisher; Nicholas W Keiser; Yi Song; Scott R Tyler; J Adam Goeken; Joann M Kinyon; Matthew C Radey; Danielle Fligg; Xiaoyan Wang; Weiliang Xie; Thomas J Lynch; Paul M Kaminsky; Mitchell J Brittnacher; Samuel I Miller; Kalpaj Parekh; David K Meyerholz; Lucas R Hoffman; Timothy Frana; Zoe A Stewart; John F Engelhardt
Journal:  Am J Pathol       Date:  2014-03-15       Impact factor: 4.307

4.  Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Aliye Uc; Dana K Andersen; Melena D Bellin; Jason I Bruce; Asbjørn M Drewes; John F Engelhardt; Christopher E Forsmark; Markus M Lerch; Mark E Lowe; Brent A Neuschwander-Tetri; Stephen J OʼKeefe; Tonya M Palermo; Pankaj Pasricha; Ashok K Saluja; Vikesh K Singh; Eva M Szigethy; David C Whitcomb; Dhiraj Yadav; Darwin L Conwell
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

5.  Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.

Authors:  Zhiwei Cai; Timea Palmai-Pallag; Pissared Khuituan; Michael J Mutolo; Clément Boinot; Beihui Liu; Toby S Scott-Ward; Isabelle Callebaut; Ann Harris; David N Sheppard
Journal:  J Physiol       Date:  2015-04-09       Impact factor: 5.182

6.  Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.

Authors:  Ziying Yan; Xingshen Sun; Zehua Feng; Guiying Li; John T Fisher; Zoe A Stewart; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2015-04-20       Impact factor: 5.695

7.  Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes.

Authors:  William R Hunt; Susu M Zughaier; Dana E Guentert; Melissa A Shenep; Michael Koval; Nael A McCarty; Jason M Hansen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-04       Impact factor: 5.464

8.  Cftr controls lumen expansion and function of Kupffer's vesicle in zebrafish.

Authors:  Adam Navis; Lindsay Marjoram; Michel Bagnat
Journal:  Development       Date:  2013-03-13       Impact factor: 6.868

9.  Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis.

Authors:  Yaling Yi; Andrew W Norris; Kai Wang; Xingshen Sun; Aliye Uc; Antoinette Moran; John F Engelhardt; Katie Larson Ode
Journal:  Am J Respir Crit Care Med       Date:  2016-10-15       Impact factor: 21.405

Review 10.  Endocrine Disorders in Cystic Fibrosis.

Authors:  Scott M Blackman; Vin Tangpricha
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.